Article Text

AB0484 Anti-CCP profile in rheumatoid arthritis during long-term etanercept treatment
  1. P. Solakov,
  2. S. Kuzmanova,
  3. S. Alimanska
  1. Clinic of Rheumatology, University Hospital, Plovdiv, Bulgaria


Background Anti-CCP antibody testing is useful in the diagnosis and prognosis of RA. We discuss anti-CCP testing with an emphasis on diagnostic performance and prognostic capability.

Objectives There aim of the present study was to investigate the effect of long-term etanercept treatment on anti-cyclic citrullinated peptide (anti-CCP).

Methods A second generation commercially available ELISA kit (CCPlus Euro-Diagnostica) were assessed. Serum samples from 31 consecutive patients with refractory RA and with positive anti-CCP test were prospectively followed during etanercept and methotrexate therapy. Autoantibodies were tested at baseline and after 6, 12 and 18 months. Before therapy, at baseline, positive anti-cyclic citrullinated peptide (anti-CCP2) test were found in 100% of patients. The proportion of patients who were positive for rheumatoid factor at baseline and after 18 months was 87.1% and 74.2% respectively.

Results Median values of the Disease Activity score (DAS) significantly decreased from 4.1 (3.8 - 4.4) at baseline, to 3.8 (3.6 - 3.9), 3.2 (3.0 - 3.4) and 2.6 (3.3 - 2.4), after 6, 12 and 18 months (p<0.001) respectively. Serum anti-CCP antibody titer at baseline was 821.39 IU/ml, and the titers for 6,12 and 18 months were 784.58, 875.61, 884.62 IU/ml respectively. Anti-CCP antibody titers exhibited a no significant reduction at 6, 12 and 18 months compared to baseline (p>0,05). Significant reduction in anti-CCP antibody titer was noted only in 6 patients.

Conclusions Despite therapy with etanercept and the persistence of significant clinical improvement as indicated by DAS, no decrease of the anti-CCP antibody titers was observed. The elevated anti-CCP antibodies retain very high during treatment of RA with etanercept.

Disclosure of Interest None Declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.